Superluminal Medicines Secures $60 Million in Series B Funding to Advance Obesity Program and Drug Discovery Platform
Amount Raised
$60 Million
Round Type
Series B
BostonBiotechnologyHealth CareInvestors
Description
Superluminal Medicines has successfully raised an oversubscribed $60 million in Series B financing led by BVF Partners. This funding will enable the company to transition from a discovery-stage platform to a clinical-stage biotechnology firm, helping to advance its lead obesity program into clinical development.
Quick answer
Superluminal Medicines raised $60 Million in a Series B round, dated September 6, 2026. Investors: Deep Track Capital, Insight Partners, Perceptive Advisors, BVF Partners, Nvidia, Catalio Capital Management, Gaingels and Cooley. Superluminal Medicines is based in Boston, Massachusetts, United States.
- How much did Superluminal Medicines raise?
- Superluminal Medicines raised $60 Million in a Series B round on September 6, 2026.
- Who invested in Superluminal Medicines?
- Deep Track Capital, Insight Partners, Perceptive Advisors, BVF Partners, Nvidia, Catalio Capital Management, Gaingels and Cooley are named as investors in this round.
- What does Superluminal Medicines do?
- Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.
- Where is Superluminal Medicines based and how big is it?
- Superluminal Medicines is based in Boston, Massachusetts, United States. Fundz records about 29 employees.
- Who are the decision-makers at Superluminal Medicines?
- Fundz holds 2 contacts at Superluminal Medicines. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Superluminal Medicines that raised within 45 days of this round, from Fundz verified event records.
- Geneticure raised $1M (Series A) on October 21, 2026.
- Total Joint Orthopedics raised $11M (Debt Financing) on October 21, 2026.
- Arctic Therapeutics raised $22M on October 21, 2026.
- Disc raised $422M (Post-IPO Equity) on October 20, 2026.
- ABM Respiratory Care raised $20M (Debt Financing) on October 20, 2026.
- Sunlight AI raised $17M (Seed) on October 19, 2026.
Who to call at Superluminal Medicines, and when
A new round usually means Superluminal Medicines is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Superluminal Medicines raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Superluminal Medicines, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Superluminal Medicines. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Superluminal Medicines raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSuperluminal Medicines raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.